BC
CBAY

Bridgefront Capital’s Cymabay Therapeutics CBAY Stock Holding History

Bridgefront Capital’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-20,724
Closed -$119K – 969
2020
Q4 		$119K Buy
+20,724
New +$157K 0.04% 558

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bridgefront Capital's CBAY Position: Q1 2021 in Review

Bridgefront Capital sold out of Cymabay Therapeutics (CBAY) in Q1 2021, closing a stake of 20,724 shares — an estimated $119K sold.

Bridgefront Capital first reported a position in CBAY in Q4 2020 and held it in 1 quarter. The position peaked at $119K in Q4 2020. 130 funds tracked by Wall St. Rank hold CBAY as of Q1 2021.

  • Bridgefront Capital reported no remaining Cymabay Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Bridgefront Capital sold 20,724 Cymabay Therapeutics shares in Q1 2021, an estimated $119K.
  • Bridgefront Capital first reported a position in Cymabay Therapeutics in Q4 2020 and held it in 1 quarter.
  • Bridgefront Capital's Cymabay Therapeutics position peaked at $119K in Q4 2020.
  • 130 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2021.

Based on Bridgefront Capital's 13F filing for Q1 2021, filed 17 May 2021.